A single-centre retrospective review [25] assessing ipilimumab plus anti-PD-1 inhibitor in patients with advanced HCC with progression on previous immune checkpoint inhibitors demonstrated that the median OS was 10.9 months (95% CI, 3.99–17.8), the median time-to-progression was 2.96 months (95% CI, 1.61–4.31), and the median duration of response was 11.5 (range, 2.76–30.3) months. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.